How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper-Reference-Cited by-同舟云学术

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Published:2022-02-09 Issue:12 Volume:88 Page:5017-5033
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Neumann Eva¹,Schreeck Filippa¹^ORCID,Herberg Jethro²^ORCID,Jacqz Aigrain Evelyne³⁴⁵^ORCID,Maitland‐van der Zee Anke H.⁶,Pérez‐Martínez Antonio⁷⁸⁹,Hawcutt Daniel B.¹⁰¹¹,Schaeffeler Elke¹,Rane Anders¹²,de Wildt Saskia N.¹³¹⁴,Schwab Matthias¹¹⁵^ORCID

Affiliation:

1. Dr Margarete Fischer‐Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen Tuebingen Germany

2. Department of Paediatric Infectious Disease, Faculty of Medicine Imperial College London London UK

3. Pediatric Pharmacology and Pharmacogenetics Hopital Universitaire Saint‐Louis Paris France

4. Clinical Investigation Center CIC1426 Hôpital Robert Debre Paris France

5. Pharmacology University of Paris Paris France

6. Department of Respiratory Medicine, Amsterdam UMC University of Amsterdam Amsterdam the Netherlands

7. Institute for Health Research La Paz University Hospital Madrid Spain

8. Pediatric Onco‐Hematology Department La Paz University Hospital Madrid Spain

9. Faculty of Medicine Autonomous University of Madrid Madrid Spain

10. Department of Women's and Children's Health University of Liverpool UK

11. NIHR Alder Hey Clinical Research Facility Alder Hey Children's Hospital Liverpool UK

12. Division of Clinical Pharmacology, Department of Laboratory Medicine Karolinska University Hospital, Karolinska Institutet Stockholm Sweden

13. Department of Pharmacology and Toxicology, Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen the Netherlands

14. Intensive Care and Department of Paediatric Surgery Erasmus MC‐Sophia Children's Hospital Rotterdam the Netherlands

15. Departments of Clinical Pharmacology, and Biochemistry and Pharmacy University of Tuebingen Tuebingen Germany

Funder

Horizon 2020 Framework Programme

Robert Bosch Stiftung

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15216

Reference170 articles.

1. Defining drug response for stratified medicine

2. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

3. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines

4. Food and Drug Administration.Table of Pharmacogenomic Biomarkers in Drug Labeling.https://www.fda.gov/drugs/science‐and‐research‐drugs/table‐pharmacogenomic‐biomarkers‐drug‐labeling#:~:text=Table%20of%20Pharmacogenomic%20Biomarkers%20in%20Drug%20Labeling%20 and%20Admini%20… %20%2023%20more%20rows. Updated August 18 2020. Accessed December 31 2020.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics in pediatric medicine and drug development;Pharmacogenomics;2022-08

2. Biomarker und Neuromonitoring zur Entwicklungsprognose nach perinataler Hirnschädigung;Monatsschrift Kinderheilkunde;2022-07-01

3. Innovative methodologies in paediatric drug development: A conect4children (c4c) special issue;British Journal of Clinical Pharmacology;2022-05-02